Prevencio's purpose is to prevent the preventable.
80% of cardiovascular disease, including heart disease and stroke, are preventable (CDC). Prevencio's personalized blood tests provide earlier detection and prevention which can diminish unnecessary procedures and related side effects, as well as improve patient outcomes.
Published in top-tier cardiology journals and presented at leading cardiovascular meetings, Prevencio's patented, proprietary technology has been used to create seven life-saving cardiovascular tests, with more in development.
Traditional diagnostic methods can be costly and inaccurate, delaying proper treatment and putting patients at risk for unnecessary exposure to radiation. We offer accurate and efficient solutions to help detect and prevent CVD, ensuring timely and effective medical care for all.
We are revolutionizing the way heart disease is detected and managed. Our HART tests are at the forefront of cutting-edge technology, providing unparalleled accuracy in diagnosing Coronary Artery Disease and predicting the risk of heart attack and stroke. Our advanced tests empower patients and healthcare professionals with the critical information they need to make informed medical decisions and take proactive measures to protect heart health. Join us in the fight against heart disease and trust Prevencio for your cardiac care needs.
"There is a huge unmet need to accurately diagnose the presence of cardiovascular and peripheral arterial diseases. Though single biomarker tests have helped to refine diagnosis and prognosis, it is clear the future will be with a multiple biomarker approach supported by cutting-edge machine learning. The data generated using Prevencio HART tests show clear evidence that we can better diagnose and risk stratify cardiovascular events (CVE; Inclusive of heart attack, stroke, and death), coronary artery disease (CAD), peripheral artery disease (PAD), aortic stenosis (AS) and amputation (AMP) risk and Acute Kidney Injury (AKI). These tests could initiate therapy and lifestyle change earlier, possibly prevent complications such as heart attacks, and with earlier and more effective treatment simultaneously improve patient quality of life. In addition to the opportunity for more appropriate care of patients, we believe HART tests could benefit cardiac clinical trials by saving time and thereby lowering overall trial costs."
”Although we have a few single biomarkers for use in the emergency department, the development of a multi-analyte diagnostic test incorporating clinical patient variables and algorithmic analysis would be invaluable and represents a game-changer for clinical medicine.”
“Prevencio’s novel AI-based approach has resulted in highly accurate and safe multiple protein, algorithmically-scored blood tests to diagnose heart disease and monitor patients’ risk of myocardial infarction, stroke, and cardiovascular death. Prevencio’s HART tests are poised to revolutionize the way we approach heart disease via diagnosis, treatment selection, and risk monitoring.”
"Single protein tests, primarily troponin, NT-proBNP, and BNP, advanced patient care but, due to the complex and multi-pathological nature of cardiovascular disease, single protein tests have inherent limitations. Prevencio’s AI-based, multi-protein, algorithm HART tests are more accurate for cardiovascular risk and diagnosing coronary artery disease as compared to single protein tests, stress tests, coronary artery calcium scores, genetic tests, and clinical risk scores.”